Cannabis Bioscience International Holdings Announces Effectiveness of Form S-1 Registration Statement

HOUSTON, TX – (NewMediaWire) – December 06, 2023 –  Cannabis Bioscience International Holdings, Inc. (OTC Pink: CBIH) announces that its registration statement on Form S-1 (File No. 333-267039) (the “Registration Statement”), filed under the Securities Act of 1933 (the “Securities Act”), was declared effective by the United States Securities and Exchange Commission (the “SEC”) on December 5, 2023. This declaration does not imply that the SEC has approved or disapproved the offer or sale of the common stock offered by the prospectus that is part of the registration statement (the “Prospectus”) or determined whether the Prospectus is truthful or complete. The Company filed the Registration Statement to register the offer and sale of 10,087,154,885 shares of its common stock at a price of $0.0008 per share. The Company is offering 6,250,000,000 of these shares and the remaining 3,837,154,885 shares may be offered by selling stockholders. The Company will receive none of the proceeds of sales by the selling stockholders. The Company has become a reporting company under Section 15(d) of the Securities Exchange Act of 1934 and is required to file annual, quarterly and other reports with the SEC thereunder. These reports will be available at www.sec.gov.

 

“We are pleased that the SEC has declared our registration statement effective, which represents a significant milestone in our history, as we continue to develop our business,” said Henry Levinski, VP and Treasurer.

The Company, headquartered in Houston, Texas, offers services in clinical trials and through Alpha Research Institute and cannabis-related education in classrooms, seminars and online through Pharmacology University. It intends to conduct clinical trials of its own cannabidiol products and to sell them.

Copies of the Prospectus may be obtained on the SEC’s website at https://www.sec.gov/Archives/edgar/data/1411057/999999999523003541/xslEFFECTX01/primary_doc.xml, by mail at Cannabis Bioscience International Holdings, Inc., 6201 Bonhomme Rd, Suite 466S, Houston, TX 77036, by phone at (214) 733-0868 or e-mail at ir@cbih.net

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

FORWARD-LOOKING STATEMENTS

Statements in this press release that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management’s current expectations, assumptions, and estimates of future operations, performance and economic conditions, and involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the statements made herein. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as “believe,” “expects,” “may,” “looks to,” “will,” “should,” “plan,” “intend,” “on condition,” “target,” “see,” “potential,” “estimates,” “preliminary,” or “anticipates” or the negative thereof or comparable terminology, or by discussion of strategy or goals or other future events, circumstances, or effects. Factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statements in this release include, but are not limited to, the risk factors set forth in the Registration Statement, statements regarding the offer and sale of securities and the terms thereof, statements about the effects of the COVID-19 pandemic on our business and the U.S. and global economies generally; our expectations regarding our financial performance; our expectations regarding future operating performance; our ability to attract and retain customers; our ability to compete in our industries; our ability to meet our liquidity needs; our ability to effectively manage our exposure to fluctuations in foreign currency exchange rates; the increased expenses associated with being a public company; the size of our addressable markets, market share, and market trends, including our ability to grow our business in the countries we have identified as near- term priorities; anticipated trends, developments, and challenges in our industry, business, and the highly competitive markets in which we operate; our ability to anticipate market needs or develop new or enhanced offerings and services to meet those needs; our ability to manage expansion into international markets and new industries; our ability to comply with laws and regulations, including laws affecting the cannabis and pharmaceutical industries, that currently apply or may become applicable to our business both in the United States and internationally; our ability to effectively manage our growth and expand our infrastructure and maintain our corporate culture; our ability to identify, recruit, and retain skilled personnel, including key members of senior management; our ability to successfully defend litigation brought against us; our ability to successfully identify, manage, and integrate any existing and potential acquisitions; our ability to maintain, protect, and enhance our intellectual property; and our intended use of the net proceeds from this offering. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

For more information contact us at:

(214) 733-0868

ir@cbih.net

Dante Picazo

CEO – CBIH

View the original release on www.newmediawire.com